Pfizer, Inc. (PFE) Shares Bought by Steinberg Global Asset Management

Steinberg Global Asset Management boosted its stake in shares of Pfizer, Inc. (NYSE:PFE) by 1.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 201,233 shares of the biopharmaceutical company’s stock after purchasing an additional 3,453 shares during the period. Steinberg Global Asset Management’s holdings in Pfizer were worth $6,759,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Asset Planning Services Ltd. lifted its position in Pfizer by 4.9% during the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after purchasing an additional 137 shares during the period. D. Scott Neal Inc. lifted its position in Pfizer by 19.3% during the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 504 shares during the period. Franklin Parlapiano Turner & Welch LLC bought a new position in Pfizer during the first quarter valued at approximately $121,000. Cascade Investment Advisors Inc. lifted its position in Pfizer by 89.1% during the second quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock valued at $157,000 after purchasing an additional 2,200 shares during the period. Finally, Patten Group Inc. lifted its position in Pfizer by 5.1% during the first quarter. Patten Group Inc. now owns 5,181 shares of the biopharmaceutical company’s stock valued at $177,000 after purchasing an additional 252 shares during the period. Institutional investors own 68.99% of the company’s stock.

In other Pfizer news, insider Alexander R. Mackenzie sold 15,000 shares of the company’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $33.50, for a total transaction of $502,500.00. Following the completion of the transaction, the insider now directly owns 151,474 shares in the company, valued at $5,074,379. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Laurie J. Olson sold 8,064 shares of the company’s stock in a transaction on Monday, August 21st. The stock was sold at an average price of $32.70, for a total transaction of $263,692.80. Following the transaction, the insider now owns 74,506 shares of the company’s stock, valued at $2,436,346.20. The disclosure for this sale can be found here. Insiders have sold 464,521 shares of company stock valued at $15,813,961 over the last 90 days. 0.06% of the stock is currently owned by company insiders.

Pfizer, Inc. (PFE) opened at 36.35 on Friday. The company’s 50-day moving average is $35.11 and its 200 day moving average is $33.75. Pfizer, Inc. has a 1-year low of $29.83 and a 1-year high of $36.60. The stock has a market capitalization of $216.19 billion, a PE ratio of 26.59 and a beta of 1.00.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. The company had revenue of $12.90 billion during the quarter, compared to analysts’ expectations of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The firm’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.64 earnings per share. Equities analysts predict that Pfizer, Inc. will post $2.56 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 3.52%. The ex-dividend date is Thursday, November 9th. Pfizer’s dividend payout ratio is presently 94.12%.

ILLEGAL ACTIVITY NOTICE: This piece was published by Stock Observer and is the sole property of of Stock Observer. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this piece can be accessed at https://www.thestockobserver.com/2017/10/13/pfizer-inc-pfe-shares-bought-by-steinberg-global-asset-management.html.

A number of brokerages recently weighed in on PFE. Jefferies Group LLC set a $35.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a research report on Wednesday, August 2nd. Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a research report on Tuesday, October 3rd. Berenberg Bank set a $39.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research report on Tuesday, August 1st. Cowen and Company set a $43.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Monday, August 14th. Finally, Vetr downgraded shares of Pfizer from a “buy” rating to a “hold” rating and set a $35.71 price target on the stock. in a research report on Wednesday, September 13th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $38.10.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply